Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Bolsas y Mercados Espanoles  >  Almirall, S.A.    ALM   ES0157097017


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Almirall : collaborates with ICMAB-CSIC and Leitat Technology Center in Nanomedicine applied to Dermatology

07/18/2017 | 10:08am EDT

Almirall, S.A. announced today the launch of Nano4Derm, a research project in collaboration with the Institute of Material Science of Barcelona from CSIC (ICMAB-CSIC), and Leitat Technology Center, focused in nanomedicine applied to treat dermatological diseases. Within the framework of this research project, new innovative formulations containing nanoencapsulated active ingredients will be developed for the topical treatment of inflammatory skin conditions, such as Acne and Psoriasis.

Nano4Derm involves the development and physico-chemical and biological characterisation of nanocapsules containing active ingredients, and the generation of scalable formulation prototypes for manufacturing nanoformulations suitable for clinical trials. These innovative formulations will address current unmet needs and challenges, such as antimicrobial resistance, and provide improved topical treatments for Acne and Psoriasis, in terms of side effects, instability of active ingredients, and skin penetration.

Under the terms of the agreement, ICMAB-CSIC and Leitat research centers will be in charge of developing the different prototypes of nanocapsules containing the active ingredients while Almirall will be responsible for the development of formulations containing the encapsulated actives. Furthermore, Almirall and Leitat will evaluate in preclinical studies both the new nanocapsules and formulations in order to select the best solution to address the unmet medical needs in the topical treatment of Acne and Psoriasis.

This agreement will lead to the development of two types of nanocapsules: Quatsomes and Polymeric Nanocapsules. Quatsomes are lipid nanoparticles with higher colloidal stability than liposomes, which favors the production of high quality, pharmaceutical formulations. They are obtained from the DELOS-SUSP, a technology developed by researchers from the Nanomol group (ICMAB-CSIC) based on the use of supercritical fluids such as CO. This technology has advantages over other manufacturing methodologies in terms of homogeneity and scalability, as it replaces the use of organic solvents by green solvents. Polymeric Nanocapsules are developed by the Leitat Technology Center, and provide versatility to the project as they can be designed with different drug release profiles depending on the needs being addressed.

This project is funded by the Spanish Ministry of Economy, Industry and Competitiveness (MINECO) through the announcement of the State Program for R&D&i (2016), orientated to the Society Challenges, modality RETOS-Collaboration 2016, and co-financed by FEDER funds from the European Commission.

About Nanomol (ICMAB-CSIC)

NANOMOL is a research group depending on the Institute of Material Science of Barcelona from CSIC, with wide expertise and recognized excellence in the synthesis, processing and study of molecular and polymeric materials with chemical, electronic, magnetic and biomedical properties. NANOMOL is also a member of Biomedical Research Networking center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) and of the technology transfer network TECNIO from ACC1Ó-Generalitat de Catalunya. The development by Nanomol of the different prototypes of nanocapsules will be performed in the ICTS 'NANBIOSIS', more specifically by the Biomaterial Processing and Nanostructuring Unit (U6) of the CIBER in Bioengineering, Biomaterials & NanomedicIne located at the ICMAB-CSIC.

About Leitat

Leitat is a multisectoral private technological center whose mission is to collaborate with companies and other entities to create economic, social and sustainable value, through R+D+2i projects and technological processes from innovation and creativity. Leitat is a brand of the private entity Acondicionamiento Tarrasense and is recognized by the Generalitat de Catalunya (ACCIÓ) and by MINECO.

The Division of Nanomedicine and nanobiosensors of Leitat develops nanosystems for therapeutic application in order to solve specific problems in safety and, absorption issues and improvement of the efficacy of some API. In addition, related to diagnosis the group develops nanoparticles for specific recognition of analytes for the improvement of the sensitivity and signal amplification of biosensor systems.

The Efficacy and Safety Unit of Leitat also participates in Nano4Derm project, which has extensive experience in the development and application of in vitro models for the toxicological and efficacy evaluation of diverse natural products, from the pharmaceutical, chemical, cosmetics and food industries. In the pharmaceutical sector, the Unit acts as a strategic provider in Drug Discovery and pharmaceutical development processes. In recent years this unit has been involved in the development and biological characterisation of micro- and nano-delivery systems for topical application.

About Almirall

Almirall is a global pharmaceutical company with a strong focus in Dermatology and Aesthetics with the mission of providing valuable medicines and medical devices to you and future generations. Our R&D is focused on Dermatology, with a wide range of programs including key indications. Through our innovative products, agreements and alliances, our work covers the entire drug value chain. Almirall is continually growing as a specialist company in a wide range of skin diseases, in order to cover our customers unmet needs.

Founded in 1943, headquartered in Barcelona, Spain, Almirall is listed on the Spanish Stock Exchange (ticker: ALM) and it has become a source of value creation for society due to its vision and the commitment of its long-standing major shareholders. In 2016, its revenues totaled 859.3 million euros and, with more than 2,000 employees, it has gradually built up a trusted presence across Europe, as well as in the US.

For more information, please visit www.almirall.com


This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other than historical, are 'forward-looking statements'. These statements are based on currently available information and on best estimates and assumptions believed to be reasonable by the Company. These statements involve risks and uncertainties beyond the Company's control. Therefore, actual results may differ materially from those stated by such forward-looking statements. The Company expressly disclaims any obligation to review or update any forward-looking statements, targets or estimates contained in this document to reflect any change in the assumptions, events or circumstances on which such forward-looking statements are based unless so required by applicable law.

Almirall SA published this content on 18 July 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 18 July 2017 14:08:11 UTC.

© Publicnow 2017
All news about ALMIRALL, S.A.
03/24KRYSTAL BIOTECH  : Launches Aesthetic Medicines Subsidiary Jeune
03/16ALMIRALL S A  : Renounces Option to Acquire US-Based Bioniz Therapeutics
02/22ALMIRALL S A  : Provides Upbeat FY21 Outlook After FY20 Profit Drops 30%
02/22ALMIRALL S A  : 2020 Full-Year Results
02/18ALMIRALL S A  : and MC2 Therapeutics enter a License, Collaboration and Commerci..
02/17PRESS RELEASE  : MC2 Therapeutics: Almirall and MC2 -2-
02/17PRESS RELEASE : MC2 Therapeutics: Almirall and MC2 Therapeutics enter a License,..
02/09ALMIRALL S A  : announces a new publication in the British Journal of Dermatolog..
02/03ALMIRALL S A  : announces Gianfranco Nazzi as new CEO
01/28ALMIRALL S A  : and Happify Health enter into strategic partnership to develop e..
More news
Sales 2021 831 M 995 M 995 M
Net income 2021 76,5 M 91,6 M 91,6 M
Net Debt 2021 285 M 342 M 342 M
P/E ratio 2021 30,4x
Yield 2021 1,36%
Capitalization 2 235 M 2 676 M 2 677 M
EV / Sales 2021 3,03x
EV / Sales 2022 2,71x
Nbr of Employees 1 787
Free-Float 40,3%
Duration : Period :
Almirall, S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALMIRALL, S.A.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 15,45 €
Last Close Price 12,55 €
Spread / Highest target 43,4%
Spread / Average Target 23,1%
Spread / Lowest Target -4,38%
EPS Revisions
Managers and Directors
Michael McClellan Chief Executive & Financial Officer
Jorge Gallardo Ballart Chairman
Bhushan D. Hardas Chief Scientific Officer
Volker Koscielny Chief Medical Officer
Eloi Crespo Cervera Senior Vice President-Industrial Operations
Sector and Competitors
1st jan.Capitalization (M$)
ALMIRALL, S.A.14.93%2 676
JOHNSON & JOHNSON1.61%419 864
ROCHE HOLDING AG-0.95%285 584
PFIZER INC.0.95%207 285
NOVARTIS AG-4.61%195 170
MERCK & CO., INC.-6.60%193 467